Our development efforts are focused on tackling some of the most urgent and underserved challenges in oncology, with a pipeline targeting renal cell carcinoma, prostate cancer, pancreatic cancer, and other high-need malignancies. Some of these programs have progressed into advanced clinical stages and are supported by a growing body of data demonstrating promising efficacy and a favorable safety profile.

We prioritize well-characterized molecular targets and indications where precision radiopharmaceuticals—spanning both diagnostic imaging and targeted therapy—can deliver substantial clinical value. By incorporating molecular imaging into patient selection and treatment planning, we aim to improve therapeutic precision, accelerate clinical decision-making, and ultimately improve outcomes in patient populations with high unmet needs.